Opening-Up of Liposomal Membranes by Talin

Total Page:16

File Type:pdf, Size:1020Kb

Opening-Up of Liposomal Membranes by Talin Proc. Natl. Acad. Sci. USA Vol. 95, pp. 1026–1031, February 1998 Biophysics Opening-up of liposomal membranes by talin AKIHIKO SAITOH,KINGO TAKIGUCHI*, YOHKO TANAKA, AND HIROKAZU HOTANI Division of Molecular Biology, Graduate School of Science, Nagoya University, Nagoya 464-01, Japan Edited by Donald M. Engelman, Yale University, New Haven, CT, and approved November 17, 1997 (received for review July 9, 1997) ABSTRACT Morphological changes of liposomes caused by generated by dissolving phospholipids in a chloroformy interactions between liposomal membranes and talin, a cytoskel- methanol solution, 98:2 (volyvol). Ten microliters each of 10 etal submembranous protein, were studied by direct, real-time mM phosphatidylethanolamine (PE) or phosphatidylcholine observation by using high-intensity dark-field microscopy. Sur- (PC) and phosphatidylglycerol (PG) or phosphatidylserine prisingly, when talin was added to a liposome solution, liposomes (PS) were mixed. The organic solvent was evaporated under a opened stable holes and were transformed into cup-shaped flow of nitrogen gas, and the lipids were further dried in vacuo liposomes. The holes became larger with increasing talin con- for at least 90 min. Forty microliters of buffer A (5 mM centration, and finally the cup-shaped liposomes were trans- TriszHCl, pH 8.0y1mMATPy5 mM DTT) was then added to formed into lipid bilayer sheets. These morphological changes the dried lipid films at 4°C. Upon liquid addition, the lipid films were reversed by protein dilution, i.e., the sheets could be transformed back into closed spherical liposomes. We demon- immediately started swelling to form liposomes. Swelling was strated that talin was localized mainly along the membrane facilitated by occasionally agitating the test tubes by hand. verges, presumably avoiding exposure of its hydrophobic portion After 30 min, the liposome suspensions were diluted 10-fold at the edge of the lipid bilayer. This is the first demonstration that with buffer A containing talin at various concentrations. We a lipid bilayer can stably maintain a free verge in aqueous added ATP in solution to examine the effect of actin on the solution. This finding refutes the established dogma that all lipid talin activity, because ATP is required to maintain the native bilayer membranes inevitably form closed vesicles and suggests activity of actin. that talin is a useful tool for manipulating liposomes. Liposomes were observed at 25°C with a dark-field micro- scope (BHF, Olympus, Tokyo). Images were recorded by using Phospholipids spontaneously assemble into bilayer mem- an SIT video camera (C-2400-08, Hamamatsu Photonics, branes in aqueous solution and necessarily form liposomes, Hamamatsu City, Japan) and were further processed with a which are closed-membrane vesicles (1). Liposomes often have digital image analyzer (IBAS, Zeiss) to enhance contrast. been studied as simplified models of biological membranes Protein. Talin was isolated from chicken gizzard according (2–5) and are now used as such in a number of applications to the method of Muguruma et al. (19). Samples were dialyzed from pharmacology to bioengineering (6), for example, as against 20 mM TriszHCl, pH 8.0y0.5 mM DTTy0.5 mM carriers of DNA vectors or anticancer drugs for internal phenylmethylsulfonyl fluoride (PMSF) and were then used. deliveries. However, studies of interaction mechanisms be- To make a concentration gradient of talin for microscope tween liposome membranes and biological components, such specimens, we used a flow cell made of a glass slide and a as DNA or protein, are now still in progress (5, 7, 8), and the coverslip that were firmly fixed together with spacers. To apply dynamic behavior of such complexes in solution has remained talin to liposomes, a drop of talin in buffer A was placed on an unclear. Therefore, real-time approaches by using optical open side of the flow cell, which had been filled with the microscopy to study the dynamic behavior of liposomes re- sulting from interactions between liposomal membranes and liposome solution. A gentle flow was then induced in the cell, biological elements are very important. thereby moving liposomes at various speeds. Slowly moving Liposomes can be visualized with several types of optical liposomes were followed in the microscope, and transforma- microscopes. In this study, we used high-intensity dark-field tions of liposomes at the buffer front containing talin were microscopy (9–11), because dark-field microscopy is the best monitored. Conversely, to dilute talin, a drop of buffer A was way to visualize the intact three-dimensional morphology and placed on an open side of the flow cell that had been filled with the dynamic behavior of individual lamellar liposomes in transformed liposomes, and the reverse processes were mon- solution, and only this type of microscopy provides real-time, itored as described above. high-contrast images. In practice, other types of high-contrast Actin was purified from rabbit skeletal muscle as described microscopes, such as phase contrast or differential interfer- previously (20). Anti-talin monoclonal antibody (T 3287) was ence, still yield poor contrast for individual lamellar liposomes. purchased from Sigma (21) and was used after 100- to 1,000- In this study, we investigated morphological changes of lipo- fold dilution with buffer A. somes caused by talin. Talin is an actin-binding, peripheral- Assay of Talin Activities. The binding activity of talin to membrane protein that localizes at focal contacts in cells and that liposomes was determined by the cosedimentation method. links actin filaments with plasma membranes through integrin Talin was added to a liposome solution and incubated at 25°C (12–15). It has also been reported that talin can bind to mem- for 1 hr. Unbound and bound proteins were separated by branes directly and can promote actin polymerization (16–18). centrifugation at 300,000 3 g for 15 min. To evaluate the effects of talin, the frequency of three kinds of membrane MATERIALS AND METHODS structures—spherical liposomes, cup-shaped, and sheet- Preparation and Observation of Liposomes. Liposomes shaped membranes—was determined by observation under were prepared as described previously (9–11). Lipid films were dark-field microscopy. The publication costs of this article were defrayed in part by page charge This paper was submitted directly (Track II) to the Proceedings office. Abbreviations: PC, phosphatidylcholine; PG, phosphatidylglycerol; payment. This article must therefore be hereby marked ‘‘advertisement’’ in PE, phosphatidylethanolamine; PS, phosphatidylserine; PMSF, phe- accordance with 18 U.S.C. §1734 solely to indicate this fact. nylmethylsulfonyl fluoride. © 1998 by The National Academy of Sciences 0027-8424y98y951026-6$2.00y0 *To whom reprint requests should be addressed. e-mail: j46037a@ PNAS is available online at http:yywww.pnas.org. nucc.cc.nagoya-u.ac.jp. 1026 Downloaded by guest on September 27, 2021 Biophysics: Saitoh et al. Proc. Natl. Acad. Sci. USA 95 (1998) 1027 FIG. 1. Transformed liposomes observed by dark-field microscopy in the presence of talin. Liposomes were prepared from PE and PG (1:1, mol:mol). (A) Spherical liposomes obtained in the absence of talin. (B) Cup-shaped liposomes observed in the presence of 0.4 mM talin; at this talin concentration, the molar ratio of protein to total phospholipids was about 1y1,000. (C) A sheet-shaped membrane has stuck to the coverslip in 1.5 mM talin. (D) A sequence of photographs showing a small spherical liposome entering a cup-shaped membrane through its opening; the spherical liposome was trapped for several minutes and then escaped through the same opening (data not shown). (E) Three-dimensional model of a cup-shaped membrane with a small spherical liposome nearby. (F) Sequential images of a freely fluctuating lipid bilayer membrane, taken at 67-ms intervals. (G) Models of the membrane corresponding to each photograph of F.(H and J) Liposomes that have three or two opening holes, respectively, observed in the presence of 1.5 mM talin. (I and K) Models corresponding to liposomes shown in photographs H and J, respectively. (Bars 5 2 mm.) Visualization of Talin Localization. To determine the local- activity as unlabeled talin as judged by the capability to transform ization of talin in transformed membranes, talin was labeled with liposomes. The localization of the labeled talin on liposomes was rhodamine iodoacetamide (R-492, Molecular Probes). Three determined with fluorescence optics assembled into a dark-field micromolar talin was incubated with 15 mM rhodamine iodoac- microscope (BHF, Olympus) (20). etamide at 37°C for 15 min. The reaction was stopped by addition of DTT to a final concentration of 5 mM, dialyzed against 20 mM RESULTS TriszHCl, pH 8.0y0.5 mM DTTy0.5 mM PMSF to remove the remaining fluorescent dye, and then concentrated by using a Morphological Change of Liposomes by Talin. Liposomes small volume concentrator (Centricon, Amicon). The dye-to- made from neutral and acidic phospholipids usually take a protein molar ratio was 0.3. The labeled talin had the same spherical shape at neutral pH and low-salt conditions, and they Downloaded by guest on September 27, 2021 1028 Biophysics: Saitoh et al. Proc. Natl. Acad. Sci. USA 95 (1998) bright and thick to look as if they are multilamellar. However, analysis of dark-field images indicates that liposomes prepared by our method are unilamellar. The light intensity scattered from liposomes depends very strongly on the number of membrane layers. It has already been shown that when unila- mellar liposomes are transformed into double-lamellar lipo- somes, the line-like images became more than 10-fold brighter (9). The line-like images of liposomes used in this study have a uniform brightness (Fig. 1A), and this brightness is almost identical to that of single-layered membranes from erythrocyte ghosts whose associated proteins have been removed by pro- tease treatment (9). When talin was added to the liposome solution, cup- shaped liposomes, which resembled a ‘‘U’’ in the dark-field image (Fig.
Recommended publications
  • Effect of Liposome Composition and Other Factors on the Targeting of Liposomes to Experimental Tumors: Biodistribution and Imaging Studies1
    (CANCER RESEARCH SO.6371-6378. October I. 1990] Effect of Liposome Composition and Other Factors on the Targeting of Liposomes to Experimental Tumors: Biodistribution and Imaging Studies1 Alberto Gabizon,2 David C. Price, John Huberty, Robert S. Bresalier, and Demetrios Papahadjopoulos Cancer Research Institute ¡A.(j., I). P.] and Department of Radiology, [D. C. P., J. H.J, L'nirersity of California, San Francisco, California 9414}; (iastroinlestinal Research Laboratories, I eteram Administration Medical Center, and Department of Medicine, I 'nirersity of California, San Francisco, California 94121 [R. S. B.J; and Liposome Technology Inc., Mento Park, California 94025 ¡A.CiJ ABSTRACT temperature, cholesterol, and careful size control result in in hibition of RES uptake with concomitant enhancement of We have examined the distribution of radiolabeled liposomes in tumor- tumor uptake (5). bearing mice after i.v. injection. Two mouse tumors (B16 melanoma, In this report, we describe tissue distribution and imaging J6456 lymphoma) and a human tumor (LS174T colon carcinoma) inoc ulated i.m., S.C.,or in the hind footpad were used in these studies. When studies with transplantable mouse and human tumor models various liposome compositions with a mean vesicle diameter of ~ 100 nm using 3 different radiolabels of liposomes. The findings here were compared using a radiolabel of gallium-67-deferoxamine, optimal indicate that the concentration of liposome-encapsulated radio- tumor localization was obtained with liposomes containing a phosphati- labels in tumors is well above that of most other tissues and dylcholine of high phase-transition temperature and a small molar frac approximates the values obtained in the liver.
    [Show full text]
  • Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
    pharmaceutics Review Liposome-Based Drug Delivery Systems in Cancer Immunotherapy Zili Gu 1 , Candido G. Da Silva 1 , Koen van der Maaden 2,3, Ferry Ossendorp 2 and Luis J. Cruz 1,* 1 Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands 2 Tumor Immunology Group, Department of Immunology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands 3 TECOdevelopment GmbH, 53359 Rheinbach, Germany Received: 1 October 2020; Accepted: 2 November 2020; Published: 4 November 2020 Abstract: Cancer immunotherapy has shown remarkable progress in recent years. Nanocarriers, such as liposomes, have favorable advantages with the potential to further improve cancer immunotherapy and even stronger immune responses by improving cell type-specific delivery and enhancing drug efficacy. Liposomes can offer solutions to common problems faced by several cancer immunotherapies, including the following: (1) Vaccination: Liposomes can improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells; (2) Tumor normalization: Liposomes can deliver drugs selectively to the tumor microenvironment to overcome the immune-suppressive state; (3) Rewiring of tumor signaling: Liposomes can be used for the delivery of specific drugs to specific cell types to correct or modulate pathways to facilitate better anti-tumor immune responses; (4) Combinational therapy: Liposomes are ideal vehicles for the simultaneous delivery of drugs to be combined with other therapies, including chemotherapy, radiotherapy, and phototherapy. In this review, different liposomal systems specifically developed for immunomodulation in cancer are summarized and discussed. Keywords: liposome; drug delivery; cancer immunotherapy; immunomodulation 1. The Potential of Immunotherapy for the Treatment of Cancer Cancer immunotherapy has been widely explored because of its durable and robust effects [1].
    [Show full text]
  • Entrapment of Citrus Limon Var. Pompia Essential Oil Or Pure Citral in Liposomes Tailored As Mouthwash for the Treatment of Oral Cavity Diseases
    pharmaceuticals Article Entrapment of Citrus limon var. pompia Essential Oil or Pure Citral in Liposomes Tailored as Mouthwash for the Treatment of Oral Cavity Diseases 1, 1, 2 3 Lucia Palmas y , Matteo Aroffu y, Giacomo L. Petretto , Elvira Escribano-Ferrer , Octavio Díez-Sales 4, Iris Usach 4, José-Esteban Peris 2, Francesca Marongiu 1, Mansureh Ghavam 5, Sara Fais 6, Germano Orrù 6, Rita Abi Rached 7, Maria Letizia Manca 1,* and Maria Manconi 1 1 Department of Scienze della Vita e dell’Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy; [email protected] (L.P.); matteo.aroff[email protected] (M.A.); [email protected] (F.M.); [email protected] (M.M.) 2 Department of Chemistry and Pharmacy, University of Sassari, 07100 Sassari, Italy; [email protected] (G.L.P.); [email protected] (J.-E.P.) 3 Biopharmaceutics and Pharmacokinetics Unit, Institute for Nanoscience and Nanotechnology, University of Barcelona, 08193 Barcelona, Spain; [email protected] 4 Department of Pharmacy, Pharmaceutical Technology and Parasitology, University of Valencia, Burjassot, 46100 Valencia, Spain; [email protected] (O.D.-S.); [email protected] (I.U.) 5 Department of Range and Watershed Management, Faculty of Natural Resources and Earth Sciences, University of Kashan, Kashan 8731753153, Iran; [email protected] 6 Department of Surgical Science, University of Cagliari, Molecular Biology Service Lab (MBS), Via Ospedale 40, 09124 Cagliari, Italy; [email protected] (S.F.); [email protected] (G.O.) 7 Centre d’Analyses et de Recherche, Unité de Recherche TVA, Laboratoire CTA, Faculté des Sciences, Université Saint-Joseph, B.P.
    [Show full text]
  • In Vitro Release Test Methods for Drug Formulations for Parenteral Applications
    dx.doi.org/10.14227/DT250418P8 Reprinted with permission. Copyright 2018. The United States Pharmacopeial Convention. All rights reserved. In Vitro Release Test Methods for Drug Formulations for Parenteral Applications Vivian Gray,a Susan Cady,b David Curran,c James DeMuth,d Okponanabofa Eradiri,e Munir Hussain,f Johannes Krämer,g John Shabushnig,h Erika Stippler,i,j a V. A. Gray Consulting, Inc, Hockessin, DE. b Boehringer Ingelheim Animal Health, North Brunswick, NJ. c GlaxoSmithKline R&D, King of Prussia, PA. d University of Wisconsin, Madison, WI. e Food and Drug Administration, Silver Spring, MD.—The views presented in this article do not necessarily reflect those of the FDA. No official support or endorsement by the Food and Drug Administration is intended or should be inferred. f Bristol-Myers Squibb Company, New Brunswick, NJ. (Retired). g PHAST, Homburg, Germany. h Insight Pharma Consulting, LLC, Marshall, MI. i United States Pharmacopeia, Rockville, MD. j Correspondence should be addressed to: Desmond G Hunt, Principal Scientific Liaison, US Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852-1790; tel: +1.301.816.8341; email: [email protected] ABSTRACT In vitro drug release testing for parenteral drug formulations could benefit from more regulatory guidance and compendial information as this testing is a part of current expectations for drug product approval. This Stimuli article discusses in vitro drug release methods for those parenteral drug formulations that are not solutions and explores the challenges involved in using these methods for each formulation type. INTRODUCTION particulate matter, sterility, bacterial endotoxins, water his Stimuli article is the work of some members of the content, aluminum content, and content uniformity.
    [Show full text]
  • Preparation and Evaluation of Liposome Containing Clove Oil
    PREPARATION AND EVALUATION OF LIPOSOME CONTAINING CLOVE OIL By Pilaslak Akrachalanont A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree MASTER OF PHARMACY Program of Pharmaceutical Technology Graduate School SILPAKORN UNIVERSITY 2008 PREPARATION AND EVALUATION OF LIPOSOME CONTAINING CLOVE OIL By Pilaslak Akrachalanont A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree MASTER OF PHARMACY Program of Pharmaceutical Technology Graduate School SILPAKORN UNIVERSITY 2008 !"#$% &'(% !)%*+!,-.&"-#,//1(",$3 .!('1( $3! ,!" 4"-#2552 .)6.&$3! ,!" The graduate school, Silpakorn University has approved and accredited the thesis title of Preparation and Evaluation of Liposome Containing Clove Oil submitted by Miss Pilaslak Akarachalanon as a partial fulfillment of the requirements for the degree of master of pharmacy, program of pharmaceutical technology. (Associate Professor Sirichai Chinatangkul, Ph.D.) Dean of graduate school ./.../... The Thesis advisors 1. Associate Professor Somlak Kongmuang, Ph.D. 2. Assistant Professor Police Captain Malai Sathirapund 3. Associate Professor Uthai Sotanaphun, Ph.D. The Thesis Examination Committee Chairman (Parichat Chomto, Ph.D.) ../../.. .Member (Prof. Garnpimol Rittidej, Ph.D.) ../../.. .Member (Assoc.Prof. Somlak Kongmuang, Ph.D.) ../../.. .Member Member (Assist.Prof. Pol.Capt. Malai Sathirapund) (Assoc.Prof. Uthai Sotanaphun, Ph.D.) ../../.. ../../ 47353202 : MAJOR : PHARMACEUTICAL TECHNOLOGY KEY WORDS : LOPOSOME / CLOVE OIL / EUGENOL / THIN FILM METHOD PILASLAK AKRACHALANONT : PREPARATION AND EVALUATION OF LIPOSOME CONTAINING CLOVE OIL. THESIS ADVISORS : ASSOC.PROF.SOMLAK KONGMUANG, Ph.D., ASSIST.PROF POL.CAPT. MALAI SATHIRAPUND, AND ASSOC.PROF. UTHAI SOTANAPHUN, Ph.D. 117 pp. This research particularly focuses on preparation of liposomes which can efficiently maintain stability and quality of clove oil. The research method used in this study can be divided into five main steps.
    [Show full text]
  • Ph and Temperature Dual-Sensitive Liposome Gel Based on Novel Cleavable Mpeg-Hz-CHEMS Polymeric Vaginal Delivery System
    International Journal of Nanomedicine Dovepress open access to scientific and medical research Open Access Full Text Article Original RESEARCH pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system Daquan Chen1,2 Background: In this study, a pH and temperature dual-sensitive liposome gel based on a Kaoxiang Sun1,2 novel cleavable hydrazone-based pH-sensitive methoxy polyethylene glycol 2000-hydrazone- Hongjie Mu1 cholesteryl hemisuccinate (mPEG-Hz-CHEMS) polymer was used for vaginal administration. Mingtan Tang3 Methods: The pH-sensitive, cleavable mPEG-Hz-CHEMS was designed as a modified pH- Rongcai Liang1,2 sensitive liposome that would selectively degrade under locally acidic vaginal conditions. The Aiping Wang1,2 novel pH-sensitive liposome was engineered to form a thermogel at body temperature and to degrade in an acidic environment. Shasha Zhou1 Results: A dual-sensitive liposome gel with a high encapsulation efficiency of arctigenin was Haijun Sun1 formed and improved the solubility of arctigenin characterized by Fourier transform infrared 1 Feng Zhao spectroscopy and differential scanning calorimetry. The dual-sensitive liposome gel with 1 Jianwen Yao a sol-gel transition at body temperature was degraded in a pH-dependent manner, and was 1,2 Wanhui Liu stable for a long period of time at neutral and basic pH, but cleavable under acidic conditions 1School of Pharmacy, Yantai (pH 5.0). Arctigenin encapsulated in a dual-sensitive liposome gel was more stable and less University, 2State Key Laboratory toxic than arctigenin loaded into pH-sensitive liposomes. In vitro drug release results indicated of Longacting and Targeting Drug Delivery Systems, Yantai, 3School of that dual-sensitive liposome gels showed constant release of arctigenin over 3 days, but showed Pharmaceutical Sciences, Shandong sustained release of arctigenin in buffers at pH 7.4 and pH 9.0.
    [Show full text]
  • Ambisome® (Amphotericin B) Liposome for Injection
    AmBisome® (amphotericin B) liposome for injection DESCRIPTION AmBisome® for Injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion. Each vial contains 50 mg of amphotericin B, USP, intercalated into a liposomal membrane consisting of approximately 0.64 mg alpha tocopherol, USP; 52 mg cholesterol, NF; 84 mg distearoyl phosphatidylglycerol, sodium salt; 213 mg hydrogenated soy phosphatidylcholine. In addition, 27 mg disodium succinate hexahydrate and 900 mg sucrose, NF are used as a buffer. AmBisome may contain hydrochloric acid and/or sodium hydroxide as pH adjusters. Following reconstitution with Sterile Water for Injection, USP, the resulting pH of the suspension is between 5-6. AmBisome is a true single bilayer liposomal drug delivery system. Liposomes are closed, spherical vesicles created by mixing specific proportions of amphophilic substances such as phospholipids and cholesterol so that they arrange themselves into multiple concentric bilayer membranes when hydrated in aqueous solutions. Single bilayer liposomes are then formed by microemulsification of multilamellar vesicles using a homogenizer. AmBisome consists of these unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. Due to the nature and quantity of amphophilic substances used, and the lipophilic moiety in the amphotericin B molecule, the drug is an integral part of the overall structure of the AmBisome liposomes. AmBisome contains true liposomes that are less than 100 nm in diameter. A schematic depiction of the liposome is presented below. Note: Liposomal encapsulation or incorporation into a lipid complex can substantially affect a drug’s functional properties relative to those of the unencapsulated drug or non-lipid associated drug. In addition, different liposomal or lipid-complex products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component.
    [Show full text]
  • United States Patent (19) 11) Patent Number: 4,767,615 Geho Et Al
    United States Patent (19) 11) Patent Number: 4,767,615 Geho et al. 45 Date of Patent: "Aug. 30, 1988 54; DENTAL THERAPY BY VESICLEDELIVERY 4,603,044 7/1986 Geho ....................................... 514/3 (75) Inventors: W. Blair Geho; Joseph Jacob; John R. OTHER PUBLICATIONS Lau, all of Wooster, Ohio Accepted Dental Therapeutics, 38th Ed., American Den 73) Assignee: Technology Unlimited, Inc., Wooster, tal Association, Chicago, Ill. 1979, p. 343. Ohio Jones et al. in Chemical Week, McGraw-Hill Inc., Jul. *) Notice: The portion of the term of this patent 30, 1986, pp. 426-5129, "Liposome Research: New Path subsequent to Jul. 29, 2003 has been for Drug Delivery'. disclaimed. Primary Examiner-Ronald W. Griffin (21) Appl. No.: 877,862 Assistant Examiner-F. T. Moezie (22 Filed: Jun. 24, 1986 Attorney, Agent, or Firm-Frijouf, Rust & Pyle 57 ABSTRACT Related U.S. Application Data A known procedure is used to prepare liposomes of 63 Continuation-in-part of Ser. No. 606,714, May 3, 1984, bipolar lipid membrane which are permeable and hence Pat. No. 4,603,044. "leak' their contents at a rate which is variable by 51) Int. Cl................................................. A61K 7/16 choice. The liposome is supplied with medication or 52 U.S. Cl. ........................................ 424/57; 424/49; cosmetic material for the oral cavity, or specifically for 424/54 the teeth and gums. The liposome is then attached to a 58) Field of Search ....................... 424/19, 21, 22, 27, molecule that has affinity for the hydroxyapatite. Thus, 424/28, 38, 49, 54, 57 the liposome will bind to oral cavity hydroxyapatite and (56) References Cited bathe the surrounding support surface with its contents for extended hours of service.
    [Show full text]
  • Development of Cationic Liposome Formulations for Intratracheal Gene Therapy of Early Lung Cancer
    © 2000 Nature America, Inc. 0929-1903/00/$15.00/ϩ0 www.nature.com/cgt Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer Yiyu Zou,1 Gang Zong,1 Yi-He Ling,2 and Roman Perez-Soler2 1Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030; and 2New York University, Rita J. & Stanley Kaplan Comprehensive Cancer Center, New York, New York 10016. Regional (intratracheal or aerosol) delivery of cationic liposome-DNA complexes for gene therapy of lung disease offers distinct advantages over systemic (intravenous) administration. However, optimal formulations for early lung cancer treatment have not been established. Therefore, we investigated Ͼ50 different liposome and micelle formulations for factors that may affect their transcription efficiency and tested the ideal formulations in an in vivo mouse model. Our data showed that cationic liposomes were generally more effective at transfecting genes than were micelles of the same lipid composition, thus suggesting a role for the bilayer structure in facilitating transfection. In addition, the transfection efficiency of liposome-delivered genes was highly dependent upon the lipid composition, lipid/DNA ratio, particle size of the liposome-DNA complex, and cell lines used. By optimizing these factors in vitro and in vivo, we developed a novel liposome formulation (DP3) suitable for intratracheal administration. Using G67 liposome as control, we found that DP3 was more effective than G67 in vitro and as effective as G67 at both preventing lung tumor growth and prolonging survival in our lung cancer mouse model. We observed a positive correlation between the in vitro p53 function and the in vivo antitumoral activities of liposome-p53 formulations, which had not been reported previously in studies of an intravenous liposome gene delivery system.
    [Show full text]
  • WO 2015/120389 Al 13 August 2015 (13.08.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/120389 Al 13 August 2015 (13.08.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/35 (2006.01) A61M 16/10 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61P 37/08 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/0 15029 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, ' February 2015 (09.02.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/937,928 10 February 2014 (10.02.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 61/971,709 28 March 2014 (28.03.2014) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 61/978,71 1 11 April 2014 ( 11.04.2014) us DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 62/105,423 20 January 20 15 (20.01.2015) us SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: PATARA PHARMA, LLC [US/US]; 11455 GW, KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Liposomal Formulations in Clinical Use: an Updated Review
    pharmaceutics Review Liposomal Formulations in Clinical Use: An Updated Review Upendra Bulbake †, Sindhu Doppalapudi †, Nagavendra Kommineni and Wahid Khan * Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India; [email protected] (U.B.); [email protected] (S.D.); [email protected] (N.K.) * Correspondence: [email protected] † These authors contributed equally to this work. Academic Editor: Murali Mohan Yallapu Received: 16 January 2017; Accepted: 23 March 2017; Published: 27 March 2017 Abstract: Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes. Keywords: liposomes; therapeutics; drug delivery; liposome technology; nanotechnology; clinical trials; marketed products 1. Introduction The concept of liposomal drug delivery system has revolutionised the pharmaceutical field. Alec Bangham, in 1961 [1], first described liposomes. Since then active research in the field of liposomes have been carried out and their applications are now well established in various areas, such as drug, biomolecules and gene delivery [2].
    [Show full text]
  • 54292-Daunoxome-Package-Insert-US-Original.Pdf
    DaunoXome® (daunorubicin citrate liposome injection) Rx only WARNINGS 1. Cardiac function should be monitored regularly in patients receiving DaunoXome (daunorubicin citrate liposome injection) because of the potential risk for cardiac toxicity and congestive heart failure. Cardiac monitoring is advised especially in those patients who have received prior anthracyclines or who have pre-existing cardiac disease or who have had prior radiotherapy encompassing the heart. 2. Severe myelosuppression may occur. 3. DaunoXome should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. 4. Dosage should be reduced in patients with impaired hepatic function. (See DOSAGE AND ADMINISTRATION) 5. A triad of back pain, flushing, and chest tightness has been reported in 13.8% of the patients (16/116) treated with DaunoXome in the Phase III clinical trial, and in 2.7% of treatment cycles (27/994). This triad generally occurs during the first five minutes of the infusion, subsides with interruption of the infusion, and generally does not recur if the infusion is then resumed at a slower rate. DESCRIPTION DaunoXome (daunorubicin citrate liposome injection) is a sterile, pyrogen-free, preservative-free product in a single use vial for intravenous infusion. DaunoXome contains an aqueous solution of the citrate salt of daunorubicin encapsulated within lipid vesicles (liposomes) composed of a lipid bilayer of distearoylphosphatidylcholine and cholesterol (2:1 molar ratio), with a mean diameter of about 45 nm. The lipid to drug weight ratio is 18.7:1 (total lipid:daunorubicin base), equivalent to a 10:5:1 molar ratio of distearoylphosphatidylcholine:cholesterol:daunorubicin.
    [Show full text]